The authors investigated the activity of sunitinib, an orally administered tyrosine kinase inhibitor. Sunitinib is active in previously treated patients with thymic carcinoma. Further studies are needed to identify potential biomarkers of activity.

READ FULL ARTICLE Curated publisher From Mdlinx